Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DW4421-N2
- Development stage
- Unknown
- Lead developer
- Daewon Pharm
- Administration
- Oral
01
Overview
**DW4421-N2** is a trial-specific drug-intervention identifier used by Daewon Pharmaceutical in a Phase 1 healthy-volunteer drug-drug interaction study of DW4421 with three nonsteroidal anti-inflammatory drugs. The public trial record lists DW4421-N2 separately from DW4421, DW4421-N1, and DW4421-N3; it does not publicly disclose the chemical identity, structure, dosage form, or mechanism of the substance designated DW4421-N2. Accordingly, DW4421-N2 should not be treated as a confirmed synonym of padoprazan, which is the active substance identified for DW4421. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07343245))
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on DW4421-N2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DW4421-N2.